Anderson, K.

patient stroke abciximab trial heparin angioplasty study placebo epilog nonhemorrhagic stroke hemorrhagic infarction treatment epistent hemorrhagic stroke group nonhemorrhagic difference epic trial low-dose intracranial platelet /iiia abciximab bolus infusion randomized thrombolytic therapy investigator therapy comparison erasmus mc percutaneou complication intervention receptor balloon angioplasty result stroke rates simoon regimen analysis circulation standard-dose 4 trials epic / hemorrhagic stroke rotterdam low-dose heparin regimen incidence syndrome artery disease thrombolytic epistent trials 8555 patients thrombotic complications disease october akkerhui tcheng .99 report stent lincoff topol califf low-dose heparin granger cb decker standard-dose heparin 2001 american anderson study drug bolus simoons ml www.jama.com glycoprotein abciximab bolus-only group event platelet aggregation stroke rate 0/914 bolus-only